Serveur d'exploration sur les pandémies grippales

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Interferon-associated therapies toward HIV control: The back and forth

Identifieur interne : 000223 ( Hal/Checkpoint ); précédent : 000222; suivant : 000224

Interferon-associated therapies toward HIV control: The back and forth

Auteurs : Nicolas Noel [France] ; Béatrice Jacquelin [France] ; Nicolas Huot [France] ; Cécile Goujard [France] ; Olivier Lambotte [France] ; Michaela Müller-Trutwin [France]

Source :

RBID : Hal:pasteur-01969821

English descriptors

Abstract

Human immunodeficiency virus (HIV) induces a persistent and incurable infection. However, the combined antiretroviral treatment (cART) has markedly changed the evolution of the infection and transformed a deadly disease into a manageable chronic infection. Withdrawal of cART generally leads though to resumption of the viral replication. The eradication of the virus from its cellular and anatomical reservoirs remains a goal-to-achieve for a cure. In this context, developing novel therapies contributing to this aim are an important field of research. Type I IFN has antiviral activity, which, before the presence of efficient anti-HIV drugs, has led to the testing of IFN-based therapeutic strategies during the early years of the pandemic. A historical overview of the results and its limitations that were put into light are reviewed here. In addition, several lessons could be drawn. For instance, the efficacy of the IFN-I depends on the timing of its administration and the context. Thus, the persistence of an endogenous IFN-signature, such as that generally observed in viremic patients, seems to be associated with a lower efficacy of IFN. Based on the lessons from previous trials, and in the context of cART and research for a cure, type I Interferon has regained interest and novel therapeutic approaches are currently tested in combination with cART, some with disappointing, other with encouraging results with regard to a reduction in the size of the HIV reservoir and/or delays in viral rebound after cessation of cART. Additional strategies are currently developed in addition to improve the antiviral function of the IFN-I, by using for instance other IFN subtypes than IFN-Iα2. In parallel, the development of innovative strategies aimed at counteracting the excessive activation of the IFN-pathways have been continued and their results are reviewed here as well. Altogether, the use of IFN-I in anti-HIV therapies has gone through distinct phases and many lessons could be drawn. Novel combinations are currently be tested that might provide interesting results.


Url:
DOI: 10.1016/j.cytogfr.2018.03.004

Links toward previous steps (curation, corpus...)


Links to Exploration step

Hal:pasteur-01969821

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Interferon-associated therapies toward HIV control: The back and forth</title>
<author>
<name sortKey="Noel, Nicolas" sort="Noel, Nicolas" uniqKey="Noel N" first="Nicolas" last="Noel">Nicolas Noel</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Jacquelin, Beatrice" sort="Jacquelin, Beatrice" uniqKey="Jacquelin B" first="Béatrice" last="Jacquelin">Béatrice Jacquelin</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Huot, Nicolas" sort="Huot, Nicolas" uniqKey="Huot N" first="Nicolas" last="Huot">Nicolas Huot</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Goujard, Cecile" sort="Goujard, Cecile" uniqKey="Goujard C" first="Cécile" last="Goujard">Cécile Goujard</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-106188" status="VALID">
<idno type="IdRef">156182254</idno>
<idno type="ISNI">0000 0004 0638 6872 </idno>
<idno type="RNSR">201019083D</idno>
<orgName>Centre de recherche en épidémiologie et santé des populations</orgName>
<orgName type="acronym">CESP</orgName>
<desc>
<address>
<addrLine>16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation>
<relation name="UMR U1018" active="#struct-81173" type="direct"></relation>
<relation active="#struct-92966" type="direct"></relation>
<relation active="#struct-300068" type="direct"></relation>
<relation active="#struct-300153" type="direct"></relation>
<relation name="U1018" active="#struct-303623" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle name="UMR U1018" active="#struct-81173" type="direct">
<org type="institution" xml:id="struct-81173" status="VALID">
<idno type="IdRef">03082057X</idno>
<idno type="ISNI">0000 0001 2323 0229 </idno>
<orgName>Université de Versailles Saint-Quentin-en-Yvelines</orgName>
<orgName type="acronym">UVSQ</orgName>
<date type="start">1991-07-22</date>
<desc>
<address>
<addrLine>55 avenue de Paris - 78035 Versailles cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.uvsq.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-92966" type="direct">
<org type="institution" xml:id="struct-92966" status="VALID">
<orgName>Université Paris-Sud - Paris 11</orgName>
<orgName type="acronym">UP11</orgName>
<desc>
<address>
<addrLine>Bâtiment 300 - 91405 Orsay cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-psud.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-300068" type="direct">
<org type="regroupinstitution" xml:id="struct-300068" status="VALID">
<orgName>Assistance publique - Hôpitaux de Paris (AP-HP)</orgName>
<orgName type="acronym">APHP</orgName>
<desc>
<address>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
<tutelle active="#struct-300153" type="direct">
<org type="institution" xml:id="struct-300153" status="VALID">
<orgName>Hôpital Paul Brousse</orgName>
<desc>
<address>
<addrLine>12 Avenue Paul Vaillant Couturier, 94800 Villejuif</addrLine>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
<tutelle name="U1018" active="#struct-303623" type="direct">
<org type="institution" xml:id="struct-303623" status="VALID">
<idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc>
<address>
<addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName>
<settlement type="city">Versailles</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="university">Université de Versailles-Saint-Quentin-en-Yvelines</orgName>
</affiliation>
</author>
<author>
<name sortKey="Lambotte, Olivier" sort="Lambotte, Olivier" uniqKey="Lambotte O" first="Olivier" last="Lambotte">Olivier Lambotte</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-421311" status="VALID">
<idno type="RNSR">201521286B</idno>
<orgName>Immunologie des Maladies Virales et Autoimmunes</orgName>
<orgName type="acronym">IMVA - U1184</orgName>
<desc>
<address>
<addrLine>Site de l'Hôpital de Bicêtre - Faculté de Médecine Paris Sud - 63 rue Gabriel Péri 94276 Le Kremlin-Bicêtre Cedex.Site du CEA de Fontenay-aux-Roses - 10, route du Panorama - BP 6 - 92265 Fontenay-aux-Roses.</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.universite-paris-saclay.fr/fr/recherche/laboratoire/centre-de-recherche-en-immunologie-des-infections-virales-et-des-maladies-auto</ref>
</desc>
<listRelation>
<relation active="#struct-92966" type="direct"></relation>
<relation name="DRF/IMETI" active="#struct-300016" type="direct"></relation>
<relation name="U1184" active="#struct-303623" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-92966" type="direct">
<org type="institution" xml:id="struct-92966" status="VALID">
<orgName>Université Paris-Sud - Paris 11</orgName>
<orgName type="acronym">UP11</orgName>
<desc>
<address>
<addrLine>Bâtiment 300 - 91405 Orsay cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-psud.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="DRF/IMETI" active="#struct-300016" type="direct">
<org type="institution" xml:id="struct-300016" status="VALID">
<orgName>Commissariat à l'énergie atomique et aux énergies alternatives</orgName>
<orgName type="acronym">CEA</orgName>
<desc>
<address>
<addrLine>Centre de SaclayCentre de GrenobleCentre de Cadaracheetc</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.cea.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="U1184" active="#struct-303623" type="direct">
<org type="institution" xml:id="struct-303623" status="VALID">
<idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc>
<address>
<addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Muller Trutwin, Michaela" sort="Muller Trutwin, Michaela" uniqKey="Muller Trutwin M" first="Michaela" last="Müller-Trutwin">Michaela Müller-Trutwin</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:pasteur-01969821</idno>
<idno type="halId">pasteur-01969821</idno>
<idno type="halUri">https://hal-pasteur.archives-ouvertes.fr/pasteur-01969821</idno>
<idno type="url">https://hal-pasteur.archives-ouvertes.fr/pasteur-01969821</idno>
<idno type="doi">10.1016/j.cytogfr.2018.03.004</idno>
<date when="2018-04">2018-04</date>
<idno type="wicri:Area/Hal/Corpus">000342</idno>
<idno type="wicri:Area/Hal/Curation">000342</idno>
<idno type="wicri:Area/Hal/Checkpoint">000223</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000223</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Interferon-associated therapies toward HIV control: The back and forth</title>
<author>
<name sortKey="Noel, Nicolas" sort="Noel, Nicolas" uniqKey="Noel N" first="Nicolas" last="Noel">Nicolas Noel</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Jacquelin, Beatrice" sort="Jacquelin, Beatrice" uniqKey="Jacquelin B" first="Béatrice" last="Jacquelin">Béatrice Jacquelin</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Huot, Nicolas" sort="Huot, Nicolas" uniqKey="Huot N" first="Nicolas" last="Huot">Nicolas Huot</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Goujard, Cecile" sort="Goujard, Cecile" uniqKey="Goujard C" first="Cécile" last="Goujard">Cécile Goujard</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-106188" status="VALID">
<idno type="IdRef">156182254</idno>
<idno type="ISNI">0000 0004 0638 6872 </idno>
<idno type="RNSR">201019083D</idno>
<orgName>Centre de recherche en épidémiologie et santé des populations</orgName>
<orgName type="acronym">CESP</orgName>
<desc>
<address>
<addrLine>16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation>
<relation name="UMR U1018" active="#struct-81173" type="direct"></relation>
<relation active="#struct-92966" type="direct"></relation>
<relation active="#struct-300068" type="direct"></relation>
<relation active="#struct-300153" type="direct"></relation>
<relation name="U1018" active="#struct-303623" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle name="UMR U1018" active="#struct-81173" type="direct">
<org type="institution" xml:id="struct-81173" status="VALID">
<idno type="IdRef">03082057X</idno>
<idno type="ISNI">0000 0001 2323 0229 </idno>
<orgName>Université de Versailles Saint-Quentin-en-Yvelines</orgName>
<orgName type="acronym">UVSQ</orgName>
<date type="start">1991-07-22</date>
<desc>
<address>
<addrLine>55 avenue de Paris - 78035 Versailles cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.uvsq.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-92966" type="direct">
<org type="institution" xml:id="struct-92966" status="VALID">
<orgName>Université Paris-Sud - Paris 11</orgName>
<orgName type="acronym">UP11</orgName>
<desc>
<address>
<addrLine>Bâtiment 300 - 91405 Orsay cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-psud.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-300068" type="direct">
<org type="regroupinstitution" xml:id="struct-300068" status="VALID">
<orgName>Assistance publique - Hôpitaux de Paris (AP-HP)</orgName>
<orgName type="acronym">APHP</orgName>
<desc>
<address>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
<tutelle active="#struct-300153" type="direct">
<org type="institution" xml:id="struct-300153" status="VALID">
<orgName>Hôpital Paul Brousse</orgName>
<desc>
<address>
<addrLine>12 Avenue Paul Vaillant Couturier, 94800 Villejuif</addrLine>
<country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
<tutelle name="U1018" active="#struct-303623" type="direct">
<org type="institution" xml:id="struct-303623" status="VALID">
<idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc>
<address>
<addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName>
<settlement type="city">Versailles</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="university">Université de Versailles-Saint-Quentin-en-Yvelines</orgName>
</affiliation>
</author>
<author>
<name sortKey="Lambotte, Olivier" sort="Lambotte, Olivier" uniqKey="Lambotte O" first="Olivier" last="Lambotte">Olivier Lambotte</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-421311" status="VALID">
<idno type="RNSR">201521286B</idno>
<orgName>Immunologie des Maladies Virales et Autoimmunes</orgName>
<orgName type="acronym">IMVA - U1184</orgName>
<desc>
<address>
<addrLine>Site de l'Hôpital de Bicêtre - Faculté de Médecine Paris Sud - 63 rue Gabriel Péri 94276 Le Kremlin-Bicêtre Cedex.Site du CEA de Fontenay-aux-Roses - 10, route du Panorama - BP 6 - 92265 Fontenay-aux-Roses.</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.universite-paris-saclay.fr/fr/recherche/laboratoire/centre-de-recherche-en-immunologie-des-infections-virales-et-des-maladies-auto</ref>
</desc>
<listRelation>
<relation active="#struct-92966" type="direct"></relation>
<relation name="DRF/IMETI" active="#struct-300016" type="direct"></relation>
<relation name="U1184" active="#struct-303623" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-92966" type="direct">
<org type="institution" xml:id="struct-92966" status="VALID">
<orgName>Université Paris-Sud - Paris 11</orgName>
<orgName type="acronym">UP11</orgName>
<desc>
<address>
<addrLine>Bâtiment 300 - 91405 Orsay cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.u-psud.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="DRF/IMETI" active="#struct-300016" type="direct">
<org type="institution" xml:id="struct-300016" status="VALID">
<orgName>Commissariat à l'énergie atomique et aux énergies alternatives</orgName>
<orgName type="acronym">CEA</orgName>
<desc>
<address>
<addrLine>Centre de SaclayCentre de GrenobleCentre de Cadaracheetc</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.cea.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="U1184" active="#struct-303623" type="direct">
<org type="institution" xml:id="struct-303623" status="VALID">
<idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc>
<address>
<addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Muller Trutwin, Michaela" sort="Muller Trutwin, Michaela" uniqKey="Muller Trutwin M" first="Michaela" last="Müller-Trutwin">Michaela Müller-Trutwin</name>
<affiliation wicri:level="1">
<hal:affiliation type="laboratory" xml:id="struct-410431" status="VALID">
<orgName>HIV, Inflammation et persistance</orgName>
<desc>
<address>
<addrLine>Département Virologie, 25-28 rue du Docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://research.pasteur.fr/fr/team/hiv-inflammation-persistence/</ref>
</desc>
<listRelation>
<relation active="#struct-300027" type="direct"></relation>
</listRelation>
<tutelles>
<tutelle active="#struct-300027" type="direct">
<org type="institution" xml:id="struct-300027" status="VALID">
<idno type="IdRef">027936643</idno>
<idno type="ISNI">0000 0001 2353 6535</idno>
<orgName>Institut Pasteur [Paris]</orgName>
<date type="start">1887-06-04</date>
<desc>
<address>
<addrLine>25-28, rue du docteur Roux, 75724 Paris cedex 15</addrLine>
<country key="FR"></country>
</address>
<ref type="url">https://www.pasteur.fr</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1016/j.cytogfr.2018.03.004</idno>
<series>
<title level="j">Cytokine and Growth Factor Reviews</title>
<idno type="ISSN">1359-6101</idno>
<imprint>
<date type="datePub">2018-04</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="mix" xml:lang="en">
<term>HIV</term>
<term>Interferon</term>
<term>cure</term>
<term>immune activation</term>
<term>reservoirs 2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Human immunodeficiency virus (HIV) induces a persistent and incurable infection. However, the combined antiretroviral treatment (cART) has markedly changed the evolution of the infection and transformed a deadly disease into a manageable chronic infection. Withdrawal of cART generally leads though to resumption of the viral replication. The eradication of the virus from its cellular and anatomical reservoirs remains a goal-to-achieve for a cure. In this context, developing novel therapies contributing to this aim are an important field of research. Type I IFN has antiviral activity, which, before the presence of efficient anti-HIV drugs, has led to the testing of IFN-based therapeutic strategies during the early years of the pandemic. A historical overview of the results and its limitations that were put into light are reviewed here. In addition, several lessons could be drawn. For instance, the efficacy of the IFN-I depends on the timing of its administration and the context. Thus, the persistence of an endogenous IFN-signature, such as that generally observed in viremic patients, seems to be associated with a lower efficacy of IFN. Based on the lessons from previous trials, and in the context of cART and research for a cure, type I Interferon has regained interest and novel therapeutic approaches are currently tested in combination with cART, some with disappointing, other with encouraging results with regard to a reduction in the size of the HIV reservoir and/or delays in viral rebound after cessation of cART. Additional strategies are currently developed in addition to improve the antiviral function of the IFN-I, by using for instance other IFN subtypes than IFN-Iα2. In parallel, the development of innovative strategies aimed at counteracting the excessive activation of the IFN-pathways have been continued and their results are reviewed here as well. Altogether, the use of IFN-I in anti-HIV therapies has gone through distinct phases and many lessons could be drawn. Novel combinations are currently be tested that might provide interesting results.</p>
</div>
</front>
</TEI>
<hal api="V3">
<titleStmt>
<title xml:lang="en">Interferon-associated therapies toward HIV control: The back and forth</title>
<author role="crp">
<persName>
<forename type="first">Nicolas</forename>
<surname>Noel</surname>
</persName>
<email type="md5">8f2c7bc1878287d663d957aec3017a65</email>
<email type="domain">aphp.fr</email>
<idno type="halauthorid">11376089</idno>
<affiliation ref="#struct-410431"></affiliation>
<affiliation ref="#struct-421311"></affiliation>
<affiliation ref="#struct-104786"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Béatrice</forename>
<surname>Jacquelin</surname>
</persName>
<idno type="halauthorid">194432</idno>
<affiliation ref="#struct-410431"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Nicolas</forename>
<surname>Huot</surname>
</persName>
<idno type="halauthorid">961101</idno>
<affiliation ref="#struct-410431"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Cécile</forename>
<surname>Goujard</surname>
</persName>
<idno type="halauthorid">85741</idno>
<affiliation ref="#struct-106188"></affiliation>
<affiliation ref="#struct-104786"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Olivier</forename>
<surname>Lambotte</surname>
</persName>
<idno type="halauthorid">176365</idno>
<affiliation ref="#struct-421311"></affiliation>
<affiliation ref="#struct-104786"></affiliation>
</author>
<author role="crp">
<persName>
<forename type="first">Michaela</forename>
<surname>Müller-Trutwin</surname>
</persName>
<email type="md5">7a1144df4d1e05cfa641bdd1533396ef</email>
<email type="domain">pasteur.fr</email>
<idno type="idhal" notation="string">michaela-muller-trutwin</idno>
<idno type="idhal" notation="numeric">172117</idno>
<idno type="halauthorid">802915</idno>
<idno type="ORCID">https://orcid.org/0000-0002-3854-2396</idno>
<affiliation ref="#struct-410431"></affiliation>
</author>
<editor role="depositor">
<persName>
<forename>Brigitte</forename>
<surname>BIDAULT</surname>
</persName>
<email type="md5">5388e6f3d7e7c02a4d0acf8b7e3bc4fc</email>
<email type="domain">pasteur.fr</email>
</editor>
<funder ref="#projanr-37855"></funder>
<funder ref="#projanr-38022"></funder>
<funder>NH was recipient of a fellowship from the French Vaccine Research Institute funded by the National Agency of Research (ANR) under reference ANR-10-LABX-77. The Infectious Disease Models and Innovative Therapies (IDMIT) center in Fontenay-aux-Roses, France, is funded by the French government’s Investissements d’Avenir program for infrastructures (PIA) under grant ANR-11-INBS-0008 and the PIA grant ANR-10-EQPX-02-01. MMT received a grant from the French Agency of AIDS Research, ANRS (AO 2017-2) and a donation from the L’OREAL Foundation.</funder>
</titleStmt>
<editionStmt>
<edition n="v1" type="current">
<date type="whenSubmitted">2019-01-04 15:23:31</date>
<date type="whenModified">2020-03-06 11:56:03</date>
<date type="whenReleased">2019-01-16 11:54:50</date>
<date type="whenProduced">2018-04</date>
<date type="whenEndEmbargoed">2019-01-16</date>
<ref type="file" target="https://hal-pasteur.archives-ouvertes.fr/pasteur-01969821/document">
<date notBefore="2019-01-16"></date>
</ref>
<ref type="file" subtype="author" n="1" target="https://hal-pasteur.archives-ouvertes.fr/pasteur-01969821/file/IFN%20back%20%20forth_NN-MMT-final.pdf">
<date notBefore="2019-01-16"></date>
</ref>
</edition>
<respStmt>
<resp>contributor</resp>
<name key="308071">
<persName>
<forename>Brigitte</forename>
<surname>BIDAULT</surname>
</persName>
<email type="md5">5388e6f3d7e7c02a4d0acf8b7e3bc4fc</email>
<email type="domain">pasteur.fr</email>
</name>
</respStmt>
</editionStmt>
<publicationStmt>
<distributor>CCSD</distributor>
<idno type="halId">pasteur-01969821</idno>
<idno type="halUri">https://hal-pasteur.archives-ouvertes.fr/pasteur-01969821</idno>
<idno type="halBibtex">noel:pasteur-01969821</idno>
<idno type="halRefHtml">Cytokine and Growth Factor Reviews, Elsevier, 2018, 40, pp.99-112. ⟨10.1016/j.cytogfr.2018.03.004⟩</idno>
<idno type="halRef">Cytokine and Growth Factor Reviews, Elsevier, 2018, 40, pp.99-112. ⟨10.1016/j.cytogfr.2018.03.004⟩</idno>
<availability status="restricted">
<licence target="http://creativecommons.org/licenses/by-nc-sa/">Attribution - NonCommercial - ShareAlike</licence>
</availability>
</publicationStmt>
<seriesStmt>
<idno type="stamp" n="PASTEUR">Institut Pasteur</idno>
<idno type="stamp" n="UNIV-PSUD">Université Paris Sud - Paris XI</idno>
<idno type="stamp" n="APHP" corresp="INSERM">AP-HP</idno>
<idno type="stamp" n="CESP" corresp="INSERM">Centre de recherche en Épidémiologie et Santé des Populations</idno>
<idno type="stamp" n="UVSQ">Université de Versailles Saint-Quentin-en-Yvelines</idno>
<idno type="stamp" n="CEA">CEA - Commissariat à l'énergie atomique</idno>
<idno type="stamp" n="INSERM-SACLAY" corresp="UNIV-PARIS-SACLAY">INSERM-SACLAY</idno>
<idno type="stamp" n="UVSQ-SACLAY" corresp="UNIV-PARIS-SACLAY">UVSQ-SACLAY</idno>
<idno type="stamp" n="UNIV-PSUD-SACLAY" corresp="UNIV-PARIS-SACLAY">Université Paris Sud pour Paris Saclay</idno>
<idno type="stamp" n="UNIV-PARIS-SACLAY">Université Paris-Saclay</idno>
<idno type="stamp" n="DAMAS">DAMAS - Design of Alloy Metals for low-mAss Structures</idno>
</seriesStmt>
<notesStmt>
<note type="audience" n="2">International</note>
<note type="popular" n="0">No</note>
<note type="peer" n="1">Yes</note>
</notesStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Interferon-associated therapies toward HIV control: The back and forth</title>
<author role="crp">
<persName>
<forename type="first">Nicolas</forename>
<surname>Noel</surname>
</persName>
<email type="md5">8f2c7bc1878287d663d957aec3017a65</email>
<email type="domain">aphp.fr</email>
<idno type="halauthorid">11376089</idno>
<affiliation ref="#struct-410431"></affiliation>
<affiliation ref="#struct-421311"></affiliation>
<affiliation ref="#struct-104786"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Béatrice</forename>
<surname>Jacquelin</surname>
</persName>
<idno type="halauthorid">194432</idno>
<affiliation ref="#struct-410431"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Nicolas</forename>
<surname>Huot</surname>
</persName>
<idno type="halauthorid">961101</idno>
<affiliation ref="#struct-410431"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Cécile</forename>
<surname>Goujard</surname>
</persName>
<idno type="halauthorid">85741</idno>
<affiliation ref="#struct-106188"></affiliation>
<affiliation ref="#struct-104786"></affiliation>
</author>
<author role="aut">
<persName>
<forename type="first">Olivier</forename>
<surname>Lambotte</surname>
</persName>
<idno type="halauthorid">176365</idno>
<affiliation ref="#struct-421311"></affiliation>
<affiliation ref="#struct-104786"></affiliation>
</author>
<author role="crp">
<persName>
<forename type="first">Michaela</forename>
<surname>Müller-Trutwin</surname>
</persName>
<email type="md5">7a1144df4d1e05cfa641bdd1533396ef</email>
<email type="domain">pasteur.fr</email>
<idno type="idhal" notation="string">michaela-muller-trutwin</idno>
<idno type="idhal" notation="numeric">172117</idno>
<idno type="halauthorid">802915</idno>
<idno type="ORCID">https://orcid.org/0000-0002-3854-2396</idno>
<affiliation ref="#struct-410431"></affiliation>
</author>
</analytic>
<monogr>
<idno type="halJournalId" status="VALID">12350</idno>
<idno type="issn">1359-6101</idno>
<title level="j">Cytokine and Growth Factor Reviews</title>
<imprint>
<publisher>Elsevier</publisher>
<biblScope unit="volume">40</biblScope>
<biblScope unit="pp">99-112</biblScope>
<date type="datePub">2018-04</date>
</imprint>
</monogr>
<idno type="doi">10.1016/j.cytogfr.2018.03.004</idno>
<idno type="pubmed">29555233</idno>
</biblStruct>
</sourceDesc>
<profileDesc>
<langUsage>
<language ident="en">English</language>
</langUsage>
<textClass>
<keywords scheme="author">
<term xml:lang="en">Interferon</term>
<term xml:lang="en">immune activation</term>
<term xml:lang="en">HIV</term>
<term xml:lang="en">cure</term>
<term xml:lang="en">reservoirs 2</term>
</keywords>
<classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
<classCode scheme="halDomain" n="sdv.imm">Life Sciences [q-bio]/Immunology</classCode>
<classCode scheme="halDomain" n="sdv.mp.vir">Life Sciences [q-bio]/Microbiology and Parasitology/Virology</classCode>
<classCode scheme="halDomain" n="sdv.mhep">Life Sciences [q-bio]/Human health and pathology</classCode>
<classCode scheme="halDomain" n="sdv.imm.imm">Life Sciences [q-bio]/Immunology/Immunotherapy</classCode>
<classCode scheme="halTypology" n="ART">Journal articles</classCode>
</textClass>
<abstract xml:lang="en">
<p>Human immunodeficiency virus (HIV) induces a persistent and incurable infection. However, the combined antiretroviral treatment (cART) has markedly changed the evolution of the infection and transformed a deadly disease into a manageable chronic infection. Withdrawal of cART generally leads though to resumption of the viral replication. The eradication of the virus from its cellular and anatomical reservoirs remains a goal-to-achieve for a cure. In this context, developing novel therapies contributing to this aim are an important field of research. Type I IFN has antiviral activity, which, before the presence of efficient anti-HIV drugs, has led to the testing of IFN-based therapeutic strategies during the early years of the pandemic. A historical overview of the results and its limitations that were put into light are reviewed here. In addition, several lessons could be drawn. For instance, the efficacy of the IFN-I depends on the timing of its administration and the context. Thus, the persistence of an endogenous IFN-signature, such as that generally observed in viremic patients, seems to be associated with a lower efficacy of IFN. Based on the lessons from previous trials, and in the context of cART and research for a cure, type I Interferon has regained interest and novel therapeutic approaches are currently tested in combination with cART, some with disappointing, other with encouraging results with regard to a reduction in the size of the HIV reservoir and/or delays in viral rebound after cessation of cART. Additional strategies are currently developed in addition to improve the antiviral function of the IFN-I, by using for instance other IFN subtypes than IFN-Iα2. In parallel, the development of innovative strategies aimed at counteracting the excessive activation of the IFN-pathways have been continued and their results are reviewed here as well. Altogether, the use of IFN-I in anti-HIV therapies has gone through distinct phases and many lessons could be drawn. Novel combinations are currently be tested that might provide interesting results.</p>
</abstract>
</profileDesc>
</hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Hal/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000223 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Hal/Checkpoint/biblio.hfd -nk 000223 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Hal
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Hal:pasteur-01969821
   |texte=   Interferon-associated therapies toward HIV control: The back and forth
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021